Platelet Indices and Cholinesterase in Diagnosis and Prognosis of Pulmonary Embolism
Clinical Laboratory, cilt.72, sa.3, ss.579-585, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 72 Sayı: 3
- Basım Tarihi: 2026
- Doi Numarası: 10.7754/clin.lab.2025.250916
- Dergi Adı: Clinical Laboratory
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Sayfa Sayıları: ss.579-585
- Anahtar Kelimeler: cholinesterase, mean platelet volume, mortality, platelet distribution width, pulmonary embolism
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background: This study aimed to investigate the diagnostic and prognostic value of platelet indices (Platelet (PLT), Platelet Distribution Width (PDW), Mean Platelet Volume (MPV) and cholinesterase activity in patients with pulmonary embolism (PE) in the emergency department (ED). Methods: This prospective observational case-control study included 60 patients diagnosed with PE through CT angiography and 40 healthy controls. The platelet indices and cholinesterase levels were measured on admission and day 3. The simplified Pulmonary Embolism Severity Index (sPESI) was calculated for risk stratification. The relationship between these parameters and mortality was analyzed. Results: The mean age was 67.25 ± 17.14 years in the PE group and 64.6 ± 18.12 years in the control group. MPV levels were significantly higher in PE patients compared to controls (10.78 ± 1.05 vs. 10.15 ± 0.96, p = 0.048), while cholinesterase levels were significantly lower (5.54 vs. 7.25, p < 0.001). Among PE patients, those who died had significantly lower cholinesterase levels (3.54 vs. 5.87, p = 0.043) and systolic blood pressure, along with higher lactate levels and sPESI scores compared to survivors. Patients with sPESI scores ≥ 1 had significantly lower cholinesterase levels compared to those with sPESI = 0 (5.08 vs. 7.19, p < 0.001). Conclusions: Our findings suggest that decreased cholinesterase levels and elevated MPV values may serve as promising biomarkers for PE diagnosis. Additionally, low cholinesterase levels appear to be associated with increased mortality risk in PE patients. These parameters, particularly cholinesterase, could potentially enhance current risk stratification tools when integrated with clinical scoring systems.